Replimune Continues R&D Spend, No Revenue in Q1 2026

TL;DR

REPL is a pure-play biotech gamble; no revenue means it's all about those clinical trial results.

AI Summary

Replimune Group, Inc. reported no revenue for the quarter ended June 30, 2025, consistent with the prior year, as it remains a clinical-stage biotechnology company. The net loss for the quarter was not explicitly stated but can be inferred from the lack of revenue and ongoing R&D expenses. Key business changes include continued investment in research and development for its oncolytic immunotherapies, with a focus on advancing its clinical pipeline. The company's strategic outlook centers on progressing its lead product candidates through clinical trials, particularly RP1 and RP2, for various cancer indications. Risks include the inherent uncertainties of clinical trial success, regulatory approval processes, and the need for significant future funding to sustain operations and development. The company's financial position as of June 30, 2025, shows a reliance on existing capital to fund operations, with no immediate revenue streams to offset expenses. The filing indicates a focus on long-term value creation through drug development rather than short-term profitability.

Why It Matters

For investors, Replimune's continued lack of revenue and reliance on capital raises underscore the high-risk, high-reward nature of biotech investments. Employees are focused on critical clinical trial execution, which directly impacts the company's future viability. Customers, specifically future cancer patients, are awaiting the potential breakthroughs from Replimune's oncolytic immunotherapies like RP1 and RP2. In the broader market, Replimune operates in a highly competitive oncology space, vying with larger pharmaceutical companies and other biotechs for market share and scientific validation, making successful clinical outcomes paramount for its competitive standing.

Risk Assessment

Risk Level: high — Replimune Group, Inc. is a clinical-stage company with no revenue generated for the quarter ended June 30, 2025, and relies entirely on its existing capital to fund operations. This lack of revenue, coupled with the inherent uncertainties and high costs of drug development, indicates a high financial and operational risk. The company's future success is entirely dependent on the successful development and regulatory approval of its product candidates.

Analyst Insight

Investors should consider Replimune a speculative long-term play, suitable only for those with a high-risk tolerance and a belief in the potential of its clinical pipeline. Monitor upcoming clinical trial data for RP1 and RP2 closely, as these will be the primary catalysts for stock movement.

Financial Highlights

revenue

$0

revenue Growth

0.0%

Key Numbers

• $0 — Revenue (No revenue generated for the quarter ended June 30, 2025, consistent with the prior year, indicating a clinical-stage company.)

Key Players & Entities

• Replimune Group, Inc. (company) — filer of the 10-Q
• RP1 (product) — lead product candidate
• RP2 (product) — product candidate in development
• June 30, 2025 (date) — end of the reporting period
• Woburn, MA (location) — business address of Replimune
• SEC (regulator) — recipient of the 10-Q filing

FAQ

Risk Factors

• Dependence on Future Funding [high — financial]: Replimune is a clinical-stage company with no product revenue, relying heavily on existing capital and the ability to secure future financing. As of June 30, 2025, the company's ability to continue as a going concern is dependent on its success in raising additional capital through equity offerings, debt financings, or strategic collaborations to fund its ongoing research and development activities.
• Clinical Trial and Regulatory Approval Uncertainty [high — regulatory]: The company's success is contingent upon the successful completion of clinical trials and obtaining regulatory approval for its product candidates, such as RP1 and RP2. Delays or adverse outcomes in these trials, or failure to gain FDA or other regulatory body approval, could significantly impact the company's ability to generate revenue and achieve profitability.
• Competition in Biotechnology [medium — market]: The biotechnology industry is highly competitive, with numerous companies developing therapies for similar cancer indications. Replimune faces competition from established pharmaceutical companies and emerging biotech firms, which could affect market penetration and pricing if its products are approved.
• Reliance on Key Personnel [medium — operational]: The company's ability to advance its pipeline relies on its scientific and management team. The loss of key personnel, particularly in research and development or executive leadership, could disrupt operations and hinder progress.

Industry Context

Replimune operates in the highly competitive and innovative biotechnology sector, specifically focusing on the development of oncolytic immunotherapies. The industry is characterized by significant R&D investment, long development cycles, and high regulatory hurdles. Trends include a growing emphasis on personalized medicine and combination therapies to improve treatment efficacy.

Regulatory Implications

The company faces significant regulatory scrutiny from bodies like the FDA. Successful navigation of clinical trial phases and subsequent approval processes are critical. Any delays, adverse findings, or changes in regulatory requirements could materially impact the timeline and viability of bringing its therapies to market.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]

Glossary

oncolytic immunotherapies

Cancer treatments that use genetically modified viruses to infect and kill cancer cells while stimulating the body's immune system to fight the cancer. (These are Replimune's core product candidates, forming the basis of their research and development efforts.)

clinical-stage biotechnology company

A company focused on developing new drugs or therapies that are currently undergoing testing in human clinical trials, rather than selling approved products. (Explains why Replimune has no revenue and is focused on R&D and future product approvals.)

RP1 and RP2

Replimune's lead product candidates, which are oncolytic immunotherapies being investigated for various cancer indications. (These are the primary assets driving the company's strategic focus and investment.)

Year-Over-Year Comparison

As a clinical-stage company, Replimune's revenue remains $0 for the quarter ended June 30, 2025, consistent with the prior year. The primary focus continues to be on advancing its pipeline, particularly RP1 and RP2, through clinical trials. No significant changes in financial metrics like net income or margins are expected due to the absence of product sales. New risks may emerge related to specific clinical trial outcomes or evolving competitive dynamics, but the core risks of clinical development and funding remain paramount.

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share REPL The Nasdaq Stock Market

Filing Documents

• repl-20250630.htm (10-Q) — 1289KB
• amendment_consultingagreem.htm (EX-10.1) — 11KB
• repl-6302025x10qxex311.htm (EX-31.1) — 11KB
• repl-6302025x10qxex312.htm (EX-31.2) — 10KB
• repl-6302025x10qxex321.htm (EX-32.1) — 5KB
• repl-6302025x10qxex322.htm (EX-32.2) — 5KB
• 0001737953-25-000013.txt ( ) — 6963KB
• repl-20250630.xsd (EX-101.SCH) — 58KB
• repl-20250630_cal.xml (EX-101.CAL) — 84KB
• repl-20250630_def.xml (EX-101.DEF) — 217KB
• repl-20250630_lab.xml (EX-101.LAB) — 686KB
• repl-20250630_pre.xml (EX-101.PRE) — 473KB
• repl-20250630_htm.xml (XML) — 817KB

FINANCIAL INFORMATION

PART I FINANCIAL INFORMATION 3 Item 1. Condensed Consolidated Financial Statements (Unaudited) 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations 4 Condensed Consolidated Statements of Comprehensive Loss 5 Condensed Consolidated Statements of Stockholders' Equity 6 Condensed Consolidated Statements of Cash Flows 7 Notes to Unaudited Condensed Consolidated Financial Statements 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 24 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 36 Item 4.

Controls and Procedures

Controls and Procedures 37

OTHER INFORMATION

PART II OTHER INFORMATION 39 Item 1.

Legal Proceedings

Legal Proceedings 39 Item 1A.

Risk Factors

Risk Factors 39 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 77 Item 3. Defaults Upon Senior Securities 77 Item 4. Mine Safety Disclosure 77 Item 5. Other Information 77 Item 6. Exhibits 77

SIGNATURES

SIGNATURES 79 2 Table of Contents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. REPLIMUNE GROUP, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Amounts in thousands, except share and per share amounts) (Unaudited) June 30, 2025 March 31, 2025 Assets Current assets: Cash and cash equivalents $ 97,373 $ 111,119 Short-term investments 305,967 372,685 Research and development incentives receivable 1,843 3,725 Prepaid expenses and other current assets 8,188 8,351 Total current assets 413,371 495,880 Property, plant and equipment, net 14,679 13,739 Research and development incentives receivable, non-current 431 — Restricted cash 1,707 1,703 Other non-current assets 1,200 1,200 Right-of-use asset - operating leases 3,918 3,998 Right-of-use asset - financing leases 34,201 34,808 Total assets $ 469,507 $ 551,328 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 15,483 $ 12,463 Accrued expenses and other current liabilities 40,041 45,916 Operating lease liabilities, current 1,220 1,184 Financing lease liabilities, current 2,820 2,799 Total current liabilities 59,564 62,362 Operating lease liabilities, non-current 2,953 3,076 Financing lease liabilities, non-current 22,542 22,729 Long term debt, net of discount 46,792 46,377 Other liabilities, non-current 941 941 Total liabilities $ 132,792 $ 135,485 Commitments and contingencies (Note 14) Stockholders' equity Common stock, $ 0.001 par value; 150,000,000 shares authorized as of June 30, 2025 and March 31, 2025; 77,807,174 and 77,085,024 shares issued and outstanding as of June 30, 2025 and March 31, 2025, respectively 78 77 Additional paid-in capital 1,367,668 1,358,897 Accumulated deficit ( 1,035,272 ) ( 948,579 ) Accumulated other comprehensive income 4,241 5,448 Total stockholders' equity 336,715 415,843 Total liabilities and stockholders' equity $ 469,507 $ 551,328 The accompanying notes are an integral part of these condensed consolidated financial statements. 3 Table of Contents REPLIMUNE GROUP,